Purple Biotech Stock Discussion

$Alta Global Group (MMA.US)$ $Reviva Pharmaceuticals (RVPH.US)$ $Qualigen Therapeutics (QLGN.US)$ $NOVONIX (NVX.US)$ $Medicus Pharma (MDCX.US)$ $Hepion Pharmaceuticals (HEPA.US)$ $Purple Biotech (PPBT.US)$ $Eterna Therapeutics (ERNA.US)$ $Elong Power (ELPW.US)$ $Venus Concept (VERO.US)$ $Biofrontera (BFRI.US)$ $Exicure (XCUR.US)$
📊⚡️📊

$Purple Biotech (PPBT.US)$ Reuters· 1 min ago
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results

$Purple Biotech (PPBT.US)$ Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
 
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants
 
Lead tribody IM1240 data demonstrated...

$Purple Biotech (PPBT.US)$ Watching for Phase 2 topline data for CM24 Before EOY

$Purple Biotech (PPBT.US)$ Reuters· just
Purple Biotech Reports Additional Positive Interim Data From Its Randomized Phase 2 Study With Its Lead Oncology Therapeutic Candidate Cm24

$Purple Biotech (PPBT.US)$
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been selected for a poster presentation at the American Associati...

$Purple Biotech (PPBT.US)$ Reuters·
Purple Biotech Receives Extension to Regain Compliance With the Nasdaq’s Minimum Bid Price Rule